Group 1 - The core point of the news is that 加科思-B (01167.HK) has entered into a capital increase agreement and a share transfer agreement with a strategic partner, involving a total payment of RMB 2 billion for acquiring 80% of 加科瑞康 [1][2] - 海松资本 will pay RMB 1.25 billion as an initial payment and RMB 750 million as a milestone payment for the acquisition [1] - After the transaction, 加科思 will own 10% of 加科瑞康, 海松资本 will own 80%, and the strategic partner will hold 10% [1] Group 2 - 加科瑞康 is focused on the internal research and development of cardiovascular disease treatment drugs and holds intellectual property related to early-stage cardiovascular research projects [1] - The transaction aligns with the company's strategic focus on developing innovative oncology products and solutions, optimizing capital allocation, and enhancing organizational efficiency [2] - The proceeds from the share transfer will be used for the research, production, and commercialization of the company's Pan-KRAS inhibitors and other innovative oncology projects [2]
加科思-B(01167.HK)拟出售心血管子公司控股权 全力聚焦KRAS、iADC等核心肿瘤管线